Physician profile
Gerald D Brown
NPI 1528029253
$6,140.35
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $1,266 · 2021: $1,118 · 2022: $768 · 2023: $1,277 · 2024: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $772.20 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $738.42 | 2019-2023 | Xarelto |
| Abbvie INC. | $659.73 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $581.14 | 2019-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $446.14 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $348.97 | 2019-2023 | |
| Glaxosmithkline, LLC. | $323.50 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $243.94 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $216.55 | 2019-2023 | Dificid, Gardasil 9, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $200.10 | 2019-2024 | |
| Amarin Pharma, INC. | $184.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $175.59 | 2020-2023 | |
| Astellas Pharma US INC | $127.78 | 2019-2023 | Veozah, Myrbetriq |
| Allergan, INC. | $125.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.34 | 2019-2024 | Jardiance |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.